LAVOMAX PILLS 125MG

Active ingredient

Lavomax - coated tablets: 1 table. contains tilaran 0.125 g, excipients: to obtain a pill weighing 0.39 g - Magnesium hydroxycarbonate hydrate (magnesium carbonate basic aqueous); Povidone (low molecular weight PVP medical, kollidon); Calcium stearate; colloidal silicon dioxide (aerosil); beeswax; Vaseline oil; sucrose; talc; tropeolin 0; titanium dioxide; high molecular weight polyethylene glycol 6000);

in the package 6, 10, 12 and 20 pcs.

butcologic action

Lavomax has antiviral, immunomodulatory effects.

Viral hepatitis A, B, C;

herpes infection, CMV infection;

infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis, etc.), urogenital and respiratory chlamydia (as part of complex therapy);

flu and other acute respiratory viral infections in adults (treatment and prevention).

Contraindications

Hypersensitivity to Lavomax;

the period of pregnancy and lactation;

children's age up to 7 years.

Adverse reactions

Allergic reactions, dyspepsia, short-term chills.

Dosage and administration

Lavomax taken orally after meals.

For non-specific prevention of viral hepatitis A - 0.125 g per week for 6 weeks.

For the treatment of viral hepatitis A, 0.125 g 2 times on the first day, then 0.125 g in 48 hours. The course dose is 1.25 g (10 tab.).

For the treatment of acute hepatitis B: the first and second days - at 0.125 g, then - at 0.125 g after 48 hours; course dose - 2 g (table 16). With a protracted course of hepatitis B, it is 0.125 g 2 times a day on the first day, then 0.125 g every 48 hours. The course dose is 2.5 g (table 20).

In chronic hepatitis B in the initial phase of treatment (2.5 g - table 20): in the first 2 days - 0.25 g each, then - at 0.125 g after 48 hours. Continuation phase - from 1.25 g (Table 10.) up to 2.5 g (20 tab.) - 0.125 g per week. The course dose of Lavomax is 3.75-5 g, the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies reflecting the degree of activity of the process.

In acute hepatitis C: on the first and second days - to 0.125 g, then - to 0.125 g in 48 hours. Course dose - 2.5 g (table 20)

In chronic hepatitis C, in the initial phase of treatment (2.5 g - table 20): in the first two days - 0.25 g, then - at 0.125 g in 48 hours. Continuation phase (2.5 g - Table 20.) - 0.125 g per week. The course dose of Lavomax is 5 g, the duration of therapy is 6 months, depending on the results of biochemical, immunological, morphological markers of the process activity.

In the treatment of influenza and other acute respiratory viral infections: in the first two days of the disease - at 0.125 g, then - at 0.125 g after 48 hours. Course dose - 0.75 g.

For the prevention of influenza and other acute respiratory viral infections: 0.125 g 1 time per week for 6 weeks.

For the treatment of herpetic, CMV infection: in the first two days - at 0.125 g, then - at 0.125 g after 48 h. Course dose - 2.5 g.

With urogenital and respiratory chlamydia: in the first two days - to 0.125 g, then - to 0.125 g in 48 hours. Course dose - 1.25 g.

In case of complex therapy of neurovirus infections: the dose is set individually, the course of treatment is 4 weeks.

Storage conditions

In a dry, dark place at a temperature of no higher than 25 ° C. Shelf life - 2 years.